Epigenomics-guided precision oncology: Chromatin variants in prostate tumor evolution

Area of Science:

• Oncology
• Epigenetics
• Genomics

Background:

• Prostate cancer frequently develops treatment resistance and aggression in 5%-30% of cases.
• Cancer cell plasticity, enabling adaptation to therapies and environments, drives metastasis and resistance.
• Genomic studies identified genetic variants, but non-genetic epigenomic events are crucial for plasticity.

Purpose of the Study:

• To explore the role of epigenomic heterogeneity in prostate cancer.
• To investigate how chromatin variants contribute to tumor evolution and therapy resistance.
• To highlight the potential of epigenomic insights for precision oncology.

Main Methods:

• Review of genomic and epigenomic studies in prostate cancer.
• Focus on chromatin variants as units of epigenomic heterogeneity.
• Discussion of single-cell sequencing and liquid biopsy epigenomic assays.

Main Results:

• Chromatin variants, changes in chromatin state, are fundamental units of epigenomic heterogeneity.
• Epigenomic heterogeneity driven by chromatin variants impacts cellular plasticity and tumor evolution.
• Single-cell and liquid biopsy epigenomic assays can uncover therapeutic targets and biomarkers.

Conclusions:

• Chromatin variants are central to understanding prostate cancer's epigenomic heterogeneity.
• Epigenomic insights offer promise for guiding precision oncology and improving patient outcomes.
• Further research into chromatin variants can lead to novel therapeutic strategies for resistant prostate cancer.